# Corvus Pharmaceuticals, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Corvus Pharmaceuticals, Inc.). ## Overview Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing immune-modulating drug candidates for cancer, inflammatory diseases, and other immune-mediated disorders. Its lead program, soquelitinib, is being advanced in both T cell lymphoma and atopic dermatitis, while additional candidates such as ciforadenant and mupadolimab remain in clinical development. ## Products & services • Soquelitinib (ITK inhibitor) for T cell lymphoma and inflammatory disease • Ciforadenant, an adenosine A2A receptor antagonist in oncology • Mupadolimab, an anti-CD73/immune-modulating antibody program • Other preclinical and clinical-stage immune-targeted product candidates - **Soquelitinib** (0%) — Lead clinical candidate targeting ITK for T cell lymphoma and immune-mediated diseases. - **Ciforadenant** (0%) — Clinical-stage oncology candidate designed to modulate adenosine signaling in solid tumors. - **Mupadolimab** (0%) — Clinical-stage immune-modulating antibody program being evaluated in cancer settings. - **Other pipeline programs** (0%) — Additional preclinical and early clinical assets targeting immune cell function. - Soquelitinib for relapsed/refractory T cell lymphomas - Soquelitinib for atopic dermatitis and other inflammatory diseases - Ciforadenant for solid tumor indications - Mupadolimab for oncology and immune modulation - Other immune-targeted product candidates in development ## Customers Corvus does not currently sell commercial products, so its near-term 'customers' are primarily clinical trial sites, contract research organizations, contract manufacturers, and academic or nonprofit research partners that support development. If approved in the future, its end customers would be physicians, hospitals, and payors treating patients with cancer or immune-mediated disease. The company’s development model is therefore driven by regulators, trial participants, and future reimbursement stakeholders rather than traditional product buyers. - **Clinical development partners** (primary) — CROs, CMOs, and specialist vendors that provide trial execution, manufacturing, and logistics support. - **Clinical trial investigators and sites** (primary) — Hospitals and research centers enrolling patients and generating efficacy/safety data for the pipeline. - **Academic and nonprofit collaborators** (secondary) — Research institutions that help with translational science, biomarker work, and early development. - **Future oncology and immunology prescribers** (emerging) — Physicians who would prescribe approved therapies for T cell lymphoma or inflammatory disease. - **Future third-party payors** (emerging) — Insurers and reimbursement bodies that would determine access and adoption after approval. - Clinical trial sites enrolling patients in oncology and inflammatory studies - CROs and vendors running preclinical and clinical development work - CMOs manufacturing drug substance and finished investigational product - Academic and nonprofit institutions supporting research collaborations - Future physicians, hospitals, and payors if any product is approved ## Geography Corvus is headquartered in South San Francisco, California and operates as a U.S.-based clinical-stage biotech with no owned manufacturing facilities. The company relies on third-party manufacturers and research partners, including foreign patent coverage and potential international development exposure, but it has not disclosed meaningful country-level revenue because it has not generated revenue to date. - Headquartered in South San Francisco, California - No owned manufacturing facilities; relies on third-party CMOs - Clinical development is primarily U.S.-based - Foreign patent coverage exists for key programs - No revenue by country disclosed because the company has no revenue ## Strategy Corvus is focused on advancing a small number of immune-targeted assets through clinical proof-of-concept, with soquelitinib as the lead program. The company is prioritizing indications where T-cell biology is well understood and where the same mechanism may support both oncology and inflammatory disease opportunities. - **Advance soquelitinib in T cell lymphoma and atopic dermatitis** (short-term) — This is the lead value driver and the most advanced program in the pipeline. - **Broaden pipeline optionality in oncology** (medium-term) — Additional indications can diversify clinical risk and extend the platform beyond one asset. - **Preserve capital through outsourcing and focused development** (short-term) — The company has no commercial revenue and must manage cash carefully until approval or partnering. - **Secure additional financing or collaborations** (medium-term) — Clinical-stage development is capital intensive and the company expects to need more funding. - Advance soquelitinib through registrational and Phase 2 studies - Use a mechanism-based approach across oncology and inflammation - Progress ciforadenant and mupadolimab selectively in solid tumors - Outsource manufacturing to stay asset-light and preserve cash - Seek additional capital and potential collaborations to fund development ## Risks Corvus is exposed to the classic risks of a clinical-stage biotech: clinical failure, regulatory delay, and the need for repeated capital raises before any product revenue exists. Its dependence on third-party manufacturers and trial vendors adds execution risk, while patent protection and competition in oncology and immunology can materially affect the value of its pipeline. - **Clinical development failure** [critical] — The company’s value depends on positive trial results for soquelitinib, ciforadenant, and mupadolimab. - **Financing risk** [high] — Corvus has no commercial revenue and expects to continue raising capital to fund operations. - **Manufacturing and supply chain dependence** [high] — The company relies on third parties for drug substance, fill-finish, labeling, and distribution. - **Regulatory approval risk** [high] — FDA approval is required before commercialization and can take years with uncertain outcomes. - **Patent and competitive risk** [medium] — Competing therapies or invalidated patents could reduce the commercial opportunity. - No product revenue yet; success depends on future approvals - Clinical trials may fail, delay, or show insufficient efficacy/safety - Additional capital will likely be needed to fund development - Third-party manufacturing and CRO dependence can disrupt timelines - Patent challenges or competition could erode pipeline value ## Accounting The company’s accounting is dominated by clinical-stage judgments rather than revenue recognition, since it has not generated revenue to date. The most important estimates are clinical trial accruals, stock-based compensation, fair value changes in warrant liabilities, and going-concern/capital resources assessments, all of which can materially affect reported losses and balance sheet volatility. - **Clinical trial accruals** — Can materially affect R&D expense and accrued liabilities - **Fair value of warrant liability** — Can distort net loss comparability across periods - **Stock-based compensation** — Raises operating expense without immediate cash outflow - **Going concern and liquidity estimates** — Important for assessing dilution and funding risk - **Lease accounting** — Affects right-of-use assets, lease liabilities, and fixed commitments - No revenue recognized to date; future revenue depends on approval or collaborations - Clinical trial accruals rely on estimates of vendor progress and timing - Stock-based compensation is a meaningful non-cash operating expense - Warrant liability fair value can create large non-cash gains or losses - Going-concern and liquidity assessments depend on cash runway assumptions --- *Last updated: 2026-04-28T19:59:23.655059+00:00*